Moleculin Biotech, Inc.
MBRXNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for MBRX. That does not mean none is planned.
Get an email about MBRX's next catalysts
Track Moleculin Biotech (MBRX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
1 upcoming event in our data (earnings).See the timeline
1 upcoming, 0 past
MBRX Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-9.90 | FQ end Sep/2026 | Call: tbd
How MBRX's past catalysts played out
Market Overview
Stock performance and key metrics
Liposomal Annamycin Injection in combination with Cytarabine Injection
Acute Myeloid Leukaemia (AML)
Liposomal Annamycin for Injection in combination with Cytarabine Injection
Acute Myeloid Leukaemia (AML)
Liposomal Annamycin (L-Annamycin)
Sarcoma,Soft Tissue
Liposomal Annamycin
Leukemia, Myeloid, Acute
MOL4239
Psoriasis
STAT3 Inhibitor WP1066
Glioblastoma, IDH-Wildtype
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Liposomal Annamycin Injection in combination with Cytarabine Injection | Phase 3 | Acute Myeloid Leukaemia (AML) | - | - |
Liposomal Annamycin for Injection in combination with Cytarabine Injection | Phase 3 | Acute Myeloid Leukaemia (AML) | - | - |
Liposomal Annamycin (L-Annamycin) | Phase 2 | Sarcoma,Soft Tissue | - | - |
Liposomal Annamycin | Phase 2 | Leukemia, Myeloid, Acute | - | - |
MOL4239 | Phase 2 | Psoriasis | - | - |
STAT3 Inhibitor WP1066 | Phase 2 | Glioblastoma, IDH-Wildtype | - | - |
Acute Myeloid Leukaemia (AML)
1 drug in this indication
Leukemia, Myeloid, Acute
1 drug in this indication
Sarcoma,Soft Tissue
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Moleculin Biotech, Inc.'s drug pipeline?→
CatalystAlert tracks 6 drug candidates in Moleculin Biotech, Inc.'s (MBRX) pipeline across Phase 3, Phase 2. Its lead program is Liposomal Annamycin for Injection in combination with Cytarabine Injection (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Moleculin Biotech, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Moleculin Biotech, Inc. (MBRX) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track MBRX biotech catalysts?→
Add MBRX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Moleculin Biotech, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.